RESEARCH TRIANGLE PARK, NC, US, October 13, 2022 /EINPresswire.com/ — Cell Microsystems Inc., a developer of advanced research tools for single cell workflows, is pleased to announce it has entered into a distribution agreement with OLS OMNI Life Sciences, a distributor of solutions in cell culture, cell counting, flow cytometry, imaging, and cell analysis.
Cell Microsystems offers the CellRaft AIR® System, an integrated platform that uses proprietary technology, including the unique CellRaft Array, to maintain cells in an unperturbed state, leading to improved viability of single cells, highly proliferative colonies, and superior clonal outgrowth. This technology dramatically increases the number of clones available for downstream applications. A one-of-a-kind solution, the CellRaft Technology allows customers to go beyond what they can do with other technologies, adding the ability to automatically isolate cells or colonies with the desired attributes in dimensions of gene expression, morphology, function, and time.
“A critical unmet need in the single cell workflow is the fast and efficient development of monoclonal colonies with high viability and rapid proliferation,” said Gary Pace, CEO at Cell Microsystems. “The current technologies in the market do not address this need, especially for the broad range of cell lines and types in use today. We are very excited to bring the CellRaft Technology to the European scientific community, and I firmly believe that OLS OMNI Life Science is the perfect channel partner for our go-to-market strategy in Europe.”
“Cell Microsystems is pleased to have OMNI Life Science represent the CellRaft AIR system in Germany, Benelux, and the Nordic region, said Scott McGinnis, Vice President of Global Sales at Cell Microsystems. “The symmetry with their current teams’ capabilities in cell-based workflows make OLS OMNI Life Sciences a perfect partner as we bring this exciting new technology to customers around the globe.”
“We are very excited to offer the CellRaft Technology to our customers. Our commercial team was very impressed with the capabilities of the instrument during training in our laboratory, and they are ready to demo the instrument for researchers,” said Dr. Andreas Friese, COO at OLS OMNI Life Science. “The CellRaft Technology fits well within our portfolio and fills a key gap in the marketplace.”
Countries covered by OLS OMNI include Austria, Belgium, Denmark, Finland, Germany, Luxembourg, Norway, and Sweden.
View the official press release.